NCT00971698

The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia

The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia. Clinical Presentation and Follow up. Splenectomy, Indications and Complications.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: HaEmek Medical Center, Israel · Academic / Other
• Sex: All
• Age: 1 Year – 35 Years
• Healthy volunteers: Not accepted

Summary

The spleen in Sickle Cell Anemia and Sickle Cell Thalassemia is usually enlarged in the first years of life but the immune protection provided is considered insufficient. In homozygous Sickle cell patients the spleen usually developed recurrent infarcts and after the first decade of age become fibrotic. Acute splenic sequestration is also frequent in those patients and this is considered as an indication for splenectomy. In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent. The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.

Detailed description

Clinical and laboratory characteristics related to the spleen in SCA patients will be studied. Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia. In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.

Conditions

• Sickle Cell Anemia
• Thalassemia

Timeline

• Start date: 2009-02-01
• Primary completion: 2010-08-01
• Completion: 2010-08-01
• First posted: 2009-09-04
• Last updated: 2011-08-26

Locations

1 site across 1 country: Israel